J
Jedd D. Wolchok
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 795
Citations - 154490
Jedd D. Wolchok is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Ipilimumab & Immune system. The author has an hindex of 140, co-authored 713 publications receiving 123336 citations. Previous affiliations of Jedd D. Wolchok include Ludwig Institute for Cancer Research & University of York.
Papers
More filters
Journal ArticleDOI
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice
Judith T. Murphy,Judith T. Murphy,Andre P. Burey,Amy M Beebe,Danling Gu,Presta Leonard G,Taha Merghoub,Jedd D. Wolchok,Jedd D. Wolchok +8 more
TL;DR: A previously undescribed lethal side effect of repetitive doses of an agonist immunomodulatory antibody is demonstrated as well as insight into the mechanism of toxicity, which may offer a means of preventing adverse effects in future clinical trials using anti-GITR or other agonist antibodies as immunotherapies.
Journal ArticleDOI
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study.
Fangwen Zou,David Faleck,Anusha Shirwaikar Thomas,Jessica Harris,Deepika Satish,Xuemei Wang,Aline Charabaty,Marc S. Ernstoff,Isabella C. Glitza Oliva,Stephen B. Hanauer,Jennifer L. McQuade,Michel Obeid,Amishi Yogesh Shah,David M. Richards,Elad Sharon,Jedd D. Wolchok,John A. Thompson,Yinghong Wang +17 more
TL;DR: In this paper, a two-center, retrospective observational cohort study of patients with immune-mediated diarrhea and colitis who received SITs following steroids from 2016 to 2020 was performed.
Journal ArticleDOI
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma
Jianda Yuan,Geoffrey Y. Ku,Matthew Adamow,Zhenyu Mu,Sapna Tandon,Drew Hannaman,Paul B. Chapman,Gary K. Schwartz,Richard D. Carvajal,Katherine S. Panageas,Alan N. Houghton,Alan N. Houghton,Jedd D. Wolchok,Jedd D. Wolchok +13 more
TL;DR: A regimen of five immunizations with pINGmuTyr administered by EP was found to be safe and resulted in Tyr-reactive immune responses in six of 15 patients at 1.5 mg dose cohort, and one patient subsequently received ipilimumab and developed an enhanced Tyr- reactive response with polyfunctional cytokine profile.
Journal ArticleDOI
The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword
TL;DR: B cells are implicated as key players in the regulation of chronic inflammation that promotes early events in epithelial carcinogenesis, linking antibodies of the adaptive immune system to innate immune responses that drive epithelium carcinogenesis.
Journal ArticleDOI
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma
Alexander N. Shoushtari,Mark J. Bluth,Debra A. Goldman,Christiana Bitas,Robert A. Lefkowitz,Michael A. Postow,Rodrigo Ramella Munhoz,Gauri Buchar,Robert Harrison Hester,Jacqueline A. Romero,Laura Fitzpatrick,Martin R. Weiser,Katherine S. Panageas,Jedd D. Wolchok,Paul B. Chapman,Richard D. Carvajal +15 more
TL;DR: Cytotoxic systemic therapy has modest activity in advanced/unresectable MM, belying its adjuvant benefit and brain imaging should be considered in routine surveillance.